• 1
    Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977; 87: 293-298.
  • 2
    Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987; 316: 1435-1440.
  • 3
    Sant M, Aareleid T, Artioli ME, et al. Ten-year survival and risk of relapse for testicular cancer: a EUROCARE high resolution study. Eur J Cancer. 2007; 43( 3): 585-592.
  • 4
    Fossa SD, Aass N, Harvei S, et al. Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br J Cancer. 2004; 90: 607-612.
  • 5
    van den Belt-Dusebout AW, Nuver J, de Wit R, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2006; 24: 467-475.
  • 6
    van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2007; 25: 4370-4378.
  • 7
    Weijl NI, Rutten MFJ, Zwinderman AH, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 2000; 18: 2169-2178.
  • 8
    Piketty AC, Flechon A, Laplanche A, et al. The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br J Cancer. 2005; 93: 909-914.
  • 9
    Nuver J, Smit AJ, van der Meer J, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol. 2005; 23: 9130-9137.
  • 10
    Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003; 21: 1513-1523.
  • 11
    Haugnes HS, Aass N, Fossa SD, et al. Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. J Cancer Surviv. 2008; 2: 128-137.
  • 12
    Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci U S A. 2002; 99: 4592-4595.
  • 13
    Fizazi K, Chen I, Logothetis CJ. Germ-cell tumor survivors: the price for cure. Ann Oncol. 2002; 13: 187-189.
  • 14
    Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet. 2006; 367: 754-765.
  • 15
    Tummala MK, Hussain A. Recent developments in germ cell tumors of the testes. Curr Opin Oncol. 2008; 20: 287-293.
  • 16
    Andreasen PA. PAI-1 - a potential therapeutic target in cancer. Curr Drug Targets. 2007; 8: 1030-1041.
  • 17
    Dass K, Ahmad A, Azmi AS, et al. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev. 2008; 34: 122-136.
  • 18
    Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem. 2004; 37: 541-548.
  • 19
    Gils A, Declerck PJ. Structure-function relationships in serpins: current concepts and controversies. Thromb Haemost. 1998; 80: 531-541.
  • 20
    Huber K. Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease. J Thromb Thrombolysis. 2001; 11: 183-193.
  • 21
    Thogersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998; 98: 2241-2247.
  • 22
    Hamsten A, Wiman B, de Faire U, et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985; 313: 1557-1563.
  • 23
    Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987; 2: 3-9.
  • 24
    Nilsson IM, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J. 1985; 290: 1453-1456.
  • 25
    Dawson SJ, Wiman B, Hamsten A, et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1993; 268: 10739-10745.
  • 26
    Eriksson P, Kallin B, van 't Hooft FM, et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A. 1995; 92: 1851-1855.
  • 27
    Tsantes AE, Nikolopoulos GK, Bagos PG, et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis. Thromb Haemost. 2007; 97: 907-913.
  • 28
    Ye Z, Liu EHC, Higgins JPT, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet. 2006; 367: 651-658.
  • 29
    Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996; 88: 3698-3703.
  • 30
    Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369: 64-67.
  • 31
    de Haas EC, Zwart N, Meijer C, et al. Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer. J Clin Oncol. 2008; 26: 1817-1823.
  • 32
    Janicke F, Schmitt M, Pache L, et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat. 1993; 24: 195-208.
  • 33
    Look MP, van Putten WLJ, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 2002; 94: 116-128.
  • 34
    Kobayashi H, Fujishiro S, Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res. 1994; 54: 6539-6548.
  • 35
    Swiercz R, Wolfe JD, Zaher A, et al. Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype. Clin Cancer Res. 1998; 4: 869-877.
  • 36
    Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000; 57: 25-40.
  • 37
    Lademann UA, Romer MU. Regulation of programmed cell death by plasminogen activator inhibitor type 1 (PAI-1). Thromb Haemost. 2008; 100: 1041-1046.
  • 38
    Castello R, Espana F, Vazquez C, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thromb Res. 2006; 117: 487-492.
  • 39
    Sternlicht MD, Dunning AM, Moore DH, et al. Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev. 2006; 15: 2107-2114.
  • 40
    Lei H, Hemminki K, Johansson R, et al. PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer. Breast Cancer Res Treat. 2008; 109: 165-175.
  • 41
    Bajou K, Maillard C, Jost M, et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene. 2004; 23: 6986-6990.
  • 42
    Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009; 27: 4839-4847.
  • 43
    Zwicker JI, Liebman HA, Neuberg D, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009; 15: 6830-6840.
  • 44
    Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 2000; 95: 1517-1532.